Imaging features of toxicities associated with immune checkpoint inhibitors.
Eur J Radiol Open
; 9: 100434, 2022.
Article
em En
| MEDLINE
| ID: mdl-35967881
ABSTRACT
The past decade has witnessed a change in landscape of cancer management with the advent of precision oncology. Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and have played an important role in improving patient survival. While the patients are living longer, treatment with ICIs are sometimes associated with adverse effects, some of which could be fatal. Radiologists can play a crucial role by early identification of some of these adverse effects during restaging scans. Our paper focuses on the imaging features of commonly occurring ICI toxicities based on organ system.
AIP, acute interstitial pneumonitis; ARDS, acute respiratory distress syndrome; CTCAE, Common Terminology Criteria for Adverse Events; CTLA-4 inhibitor, Cytotoxic T-lymphocyte antigen- 4 inhibitor; Colitis; FDA, Food and Drug Administration; Hepatitis; ICI, Immune check point inhibitor; Immune check point inhibitors toxicity; LGE, late Gadolinium enhancement; NSCLC, non-small cell lung cancer; NSIP, non-specific interstitial pneumonia; OP, organizing pneumonia; PD-1 inhibitor, programmed cell death-1 inhibitor; PD-L1 inhibitor, programmed cell death ligand-1 inhibitor; PFS, progression free survival; Pancreatitis; Pneumonitis; RRP, radiation recall pneumonitis; irAE, immune-related adverse event
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article